Viridian Therapeutics (VRDN) Short Interest Ratio & Short Volume → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free VRDN Stock Alerts $14.33 -0.34 (-2.32%) (As of 03:22 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Viridian Therapeutics Short Interest DataCurrent Short Volume9,310,000 sharesPrevious Short Volume9,730,000 sharesChange Vs. Previous Month-4.32%Dollar Volume Sold Short$123.45 millionShort Interest Ratio / Days to Cover10.2Last Record DateApril 30, 2024Outstanding Shares63,820,000 sharesPercentage of Shares Shorted14.59%Today's Trading Volume391,620 sharesAverage Trading Volume913,800 sharesToday's Volume Vs. Average43% Short Selling Viridian Therapeutics ? Sign up to receive the latest short interest report for Viridian Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVRDN Short Interest Over TimeVRDN Days to Cover Over TimeVRDN Percentage of Float Shorted Over Time Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. Viridian Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20249,310,000 shares $123.45 million -4.3%N/A10.2 $13.26 4/15/20249,730,000 shares $152.18 million +2.8%N/A10.8 $15.64 3/31/20249,470,000 shares $165.82 million +24.3%N/A9.8 $17.51 3/15/20247,620,000 shares $130.23 million +0.7%N/A7.8 $17.09 2/29/20247,570,000 shares $141.63 million -2.3%N/A7.9 $18.71 2/15/20247,750,000 shares $149.03 million -8.0%N/A8.5 $19.23 Get the Latest News and Ratings for VRDN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20248,420,000 shares $162.09 million +4.0%N/A9.2 $19.25 1/15/20248,100,000 shares $179.33 million -6.4%N/A8.6 $22.14 12/31/20238,650,000 shares $188.40 million +2.3%N/A9.5 $21.78 12/15/20238,460,000 shares $162.60 million -0.5%N/A9.7 $19.22 11/30/20238,500,000 shares $142.29 million +2.7%N/A10.9 $16.74 11/15/20238,280,000 shares $132.31 million +1.5%N/A11 $15.98 10/31/20238,160,000 shares $102 million +6.8%N/A11.6 $12.50 10/15/20237,640,000 shares $94.28 million -19.1%N/A11.9 $12.34 9/30/20239,440,000 shares $144.81 million +1.1%N/A13.4 $15.34 9/15/20239,340,000 shares $163.73 million -1.3%N/A13.4 $17.53 8/31/20239,460,000 shares $171.89 million +9.2%N/A12.7 $18.17 8/15/20238,660,000 shares $169.39 million +39.2%N/A11.7 $19.56 7/31/20236,220,000 shares $116.69 million -17.0%N/A7.8 $18.76 7/15/20237,490,000 shares $166.43 million +11.0%N/A9.7 $22.22 6/30/20236,750,000 shares $160.58 million +11.2%N/A9.1 $23.79 6/15/20236,070,000 shares $169.17 million +6.7%N/A9.3 $27.87 5/31/20235,690,000 shares $135.59 million +30.5%N/A9.5 $23.83 5/15/20234,360,000 shares $102.15 million +24.9%N/A7.2 $23.43 4/30/20233,490,000 shares $97.82 million -1.7%N/A6.2 $28.03 4/15/20233,550,000 shares $89.46 million +2.9%N/A6.7 $25.20 3/31/20233,450,000 shares $87.77 million +24.1%N/A5.9 $25.44 3/15/20232,780,000 shares $79.15 million +4.5%N/A5 $28.47 2/28/20232,660,000 shares $87.14 million No ChangeN/A4.6 $32.76 2/15/20232,660,000 shares $86.88 million +12.2%N/A4.2 $32.66 1/31/20232,370,000 shares $86.55 million -3.3%N/A3.7 $36.52 1/15/20232,450,000 shares $88.76 million -11.2%N/A3.9 $36.23 12/30/20222,760,000 shares $80.62 million +13.6%N/A4.5 $29.21 12/15/20222,430,000 shares $66.80 million -16.5%N/A4.4 $27.49 11/30/20222,910,000 shares $73.54 million +2.8%N/A5.6 $25.27 11/15/20222,830,000 shares $64.65 million +25.2%N/A6 $22.85 10/31/20222,260,000 shares $44.97 million +1.4%N/A2.8 $19.90 10/15/20222,230,000 shares $46.76 million +5.2%N/A2.8 $20.97 9/30/20222,120,000 shares $43.48 million +11.0%N/A2.8 $20.51 9/15/20221,910,000 shares $43.68 million +34.5%N/A2.4 $22.87Top 5 Tech Stocks to Buy for 2024 (Ad)Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.Click here to sign up for our free report & newsletter VRDN Short Interest - Frequently Asked Questions What is Viridian Therapeutics' current short interest? Short interest is the volume of Viridian Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 9,310,000 shares of VRDN short. Learn More on Viridian Therapeutics' current short interest. What is a good short interest ratio for Viridian Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRDN shares currently have a short interest ratio of 10.0. Learn More on Viridian Therapeutics's short interest ratio. Is Viridian Therapeutics' short interest increasing or decreasing? Viridian Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 9,310,000 shares, a decline of 4.3% from the previous total of 9,730,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Viridian Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Viridian Therapeutics: Castle Biosciences, Inc. (5.22%), Fulgent Genetics, Inc. (3.48%), CareDx, Inc (10.57%), Celcuity Inc. (6.24%), Veracyte, Inc. (5.74%), Sera Prognostics, Inc. (1.11%), Psychemedics Co. (0.35%), Guardant Health, Inc. (8.30%), Arrowhead Pharmaceuticals, Inc. (7.74%), Fortrea Holdings Inc. (7.41%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Viridian Therapeutics stock? Short selling VRDN is an investing strategy that aims to generate trading profit from Viridian Therapeutics as its price is falling. VRDN shares are trading up $0.33 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viridian Therapeutics? A short squeeze for Viridian Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRDN, which in turn drives the price of the stock up even further. How often is Viridian Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRDN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Castle Biosciences Short Interest Data Fulgent Genetics Short Interest Data CareDx Short Interest Data Celcuity Short Interest Data Veracyte Short Interest Data Sera Prognostics Short Interest Data Psychemedics Short Interest Data Guardant Health Short Interest Data Arrowhead Pharmaceuticals Short Interest Data Fortrea Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VRDN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport Societyis this a buy and hold stock?Tips4TradersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving TrendsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings